Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#2 Fake World Assets Fake World Assets +18.28%
#3 Status Status +17.90%
#4 GoPlus Security GoPlus Security +11.51%
#5 Ontology Gas Ontology Gas +10.01%
#6 Bedrock Bedrock +7.70%
#7 DMT-NAT DMT-NAT +7.61%
#8 Cap Cap +6.73%
#9 Provenance Blockchain Provenance Blockchain +6.73%
#10 Janction Janction +5.45%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Rang in aandelen #33997
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Aandeelprijs
$0.1502
Laatst gesynchroniseerd: 2024-11-04
Marktkapitalisatie
$6.43M
Verandering (1 dag)
-5.45%
Verandering (1 jaar)
0.00%
Land
US
Handel Renalytix Plc (RNLX)

Categorie

Healthcare
P/B-ratio voor Renalytix Plc (RNLX)
P/B-ratio op August 2026 TTM: -1.43
Volgens de meest recente financiële rapporten en aandelenkoers van Renalytix Plc is de huidige P/B-ratio (TTM) -1.43. Eind 2023 had het bedrijf een P/B-ratio van 6.50.
P/B-ratiohistoriek voor Renalytix Plc van 2018 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) -1.43 -17.55%
2024 -1.73 -126.57%
2023 6.50 237.16%
2022 1.93 -83.22%
2021 11.50 5.79%
2020 10.87 6.56%
2019 10.20 -100.03%
2018 -30.05K 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 3.0416 -313.25%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 48.0487 -3,468.77%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 6.2063 -535.13%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 21.0676 -1,577.08%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US